Efficacy and safety of netakimab, a novel anti-IL-17 monoclonal antibody, in patients with moderate to severe plaque psoriasis. Results of a 54-week randomized double-blind placebo-controlled PLANETA clinical trial

• Main Authors: Luis Puig (Author), Andrey L. Bakulev (Author), Muza M. Kokhan (Author), Alexey V. Samtsov (Author), Vladislav R. Khairutdinov (Author), Maria A. Morozova (Author), Nikita A. Zolkin (Author), Ivan V. Kuryshev (Author), Alexey N. Petrov (Author), Antonina V. Artemeva (Author), Arina V. Zinkina-Orikhan (Author)
• Format: Book
• Published: State Scientific Center of Dermatovenereology and Cosmetology, 2021-10-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background. Netakimab (NTK), an original humanized anti-interleukin-17 monoclonal antibody, showed therapeutic efficacy in moderate to severe plaque psoriasis in a phase 2 clinical study. Herein we report the results of 54 weeks of a phase 3 trial. Aim. To evaluate the efficacy and safety of two NTK...